Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3356-3361

  Wu, Xifeng ^a   Tortolero Luna, Guillermo ^a   Zhao, Hua ^a   Phatak, Deepali ^a   Spitz, Margaret R ^a   Follen, Michele ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; SOMATOMEDIN C;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; ETHNOLOGY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; ODDS RATIO; PRECANCEROUS CONDITIONS; RISK; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0042334841     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. American Cancer Society. Cancer Facts & Figures 2003. Atlanta, GA: American Cancer Society, 2003.
2. Schoell, W. M., Janicek, M. F., and Mirhashemi, R. Epidemiology and biology of cervical cancer. Semin. Surg. Oncol., 16: 203-211, 1999.
3. Macaulay, V. M. Insulin-like growth factors and cancer. Br. J. Cancer, 65: 311-320, 1992.
4. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16: 3-34, 1995.
5. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. Insulin-like growth factor 1 (IGF-I) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anti-cancer drugs. Cancer Res., 57: 2687-2693, 1997.
6. Parrizas, M., and LeRoith, D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology, 138: 1355-1358, 1997.
7. Stiles, A. D., and D'Ercole, A. J. The insulin-like growth factors and the lung. Am. J. Respir. Cell Mol. Biol., 3: 93-100, 1990.
8. Prager, D., Li, H. L., Asa, S., and Melmed, S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc. Natl. Acad. Sci. USA, 91: 2181-2185, 1994.
9. LeRoith, D., Werner, H., Beitner-Johnson, D., and Roberts, C. T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev., 16: 143-163, 1995.
10. Wang, L., Ma, W., Markovich, R., Lee, W. L., and Wang, P. H. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology, 139: 1354-1360, 1998.
11. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., and Wilkinson, P. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Wash. DC), 279: 563-566, 1998.
12. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., and Lagiou, P. Insulin like-growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. (Bethesda), 90: 911-915, 1998.
13. Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., and Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. (Bethesda), 91: 151-156, 1999.
14. Wu, X., Yu, H., Amos, C. I., Hong, W. K., and Spitz, M. R. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J. Natl. Cancer Inst. (Bethesda), 92: 737-743, 2000.
15. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., and Deroo, B. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-1396, 1998.
16. Kaaks, R., Toniolo, P., Akhmedkhanov, A., Lukanova, A., Biessy, C., and Dechaud, H. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J. Natl. Cancer Inst. (Bethesda), 92: 1592-1600, 2000.
17. Toniolo, P., Bruning, P. F., Akhmedkhanov, A., Bonfrer, J. M., Koenig, K. L., and Lukanova, A. Serum insulin-like growth factor-I and breast cancer. Int. J. Cancer, 88: 828-832, 2000.
18. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., and Hennekens, C. H. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. (Bethesda), 91: 620-625, 1999.
19. Pollak, M. Insulin-like growth factor physiology and cancer risk. Eur. J. Cancer, 36: 1224-1228, 2000.
20. Pollak, M. Insulin-like growth factors and prostate cancer. Epidemiol. Rev., 23: 59-66, 2001.
21. Spitz, M. R., Barnett, M. J., Goodman, G. E., Thornquist, M. D., Wu, X., and Pollak, M. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the β-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol. Biomark. Prev., 11: 1413-1418, 2002.
22. De Mellow, J. S., and Baxter, R. C. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem. Biophys. Res. Commun., 156: 199-204, 1988.
23. Pratt, S. E., and Pollak, M. N. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem. Biophys. Res. Commun., 198: 292-297, 1994.
24. Chen, J. C., Shao, Z. M., Sheikh, M. S., Hussain, A., LeRoith, D., and Roberts, C. T., Jr. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J. Cell. Physiol., 158: 69-78, 1994.
25. Steller, M. A., Delgado, C. H., and Zou, Z. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc. Natl. Acad. Sci. USA, 92: 11970-11974, 1995.
26. Steller, M. A., Delgado, C. H., Bartels, C. J., Woodworth, C. D., and Zou, Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res., 56: 1761-1765, 1996.
27. Ayabe, T., Tsutsumi, O., Sakai, H., Yoshikawa, H., Yano, T., Kurimoto, F., and Taketani, Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr. J., 44: 419-424, 1997.
28. Litle, V. R., Leavenworth, J. D., Darragh, T. M., Kosinski, L. A., Moore, D. H., II, Smith-McCune, K. K., Warren, R. S., Palefsky, J. M., and Welton, M. L. Angiogenesis, proliferation, and apoptosis in anal high-grade squamous intraepithelial lesions. Dis. Colon Rectum, 43: 346-352, 2000.
29. Bustin, S. A., and Jenkins, P. J. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol. Med., 7: 447-454, 2001.
30. Hembree, J. R., Agarwal, C., and Eckert, R. L. Epidermal growth factor suppresses insulin-like growth factor binding protein 3 levels in human papillomavirus type 16-immortalized cervical epithelial cells and thereby potentiates the effects of insulin-like growth factor 1. Cancer Res., 54: 3160-3166, 1994.
31. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189: 12-19, 1999.
32. Nakamura, K., Hongo, A., Kodama, J., Miyagi, Y., Yoshinouchi, M., and Kudo, T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res., 60: 760-765, 2000.
33. Berger, A. J., Baege, A., Guillemette, T., Deeds, J., Meyer, R., Disbrow, G., Schlegel, R., and Schlegel, R. Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am. J. Pathol., 161: 603-610, 2002.
34. Gurgan, T., Bukulmez, O., Yarali, H., Tanir, M., and Akyildiz, S. Serum and peritoneal fluid levels of IGF I and II and insulin-like growth binding protein-3 in endometriosis. J. Reprod. Med., 44: 450-454, 1999.
35. Kaplan, P. J., Mohan, S., Cohen, P., Foster, B. A., and Greenberg, N. M. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res., 59: 2203-2209, 1999.
36. Vadgama, J. V., Wu, Y., Datta, G., Khan, H., and Chillar, R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology (Basel), 57: 330-340, 1999.
37. el Atiq, F., Garrouste, F., Remacle-Bonnet, M., Sastre, B., and Pommier, G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int. J. Cancer, 57: 491-497, 1994.
38. Del Giudice, M. E., Fantus, I. G., Ezzat, S., McKeown-Eyssen, G., Page, D., and Goodwin, P. J. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat., 47: 111-120, 1998.
39. Ballard, F. J., Knowles, S. E., Walton, P. E., Edson, K., Owens, P. C., and Mohler, M. A. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. J. Endocrinol., 128: 197-204, 1991.
40. Conover, C. A., and Powell, D. R. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology, 129: 710-716, 1991.